Through its parent company, GHN Pharma AB, GHN Pharma Metabolic AB have access to international competence and a Global network covering 90 countries.
Through the local presence in the Nordic countries, GHN Pharma Metabolic are able to incorporate a global outlook and combine this with local demands and requests. Through this strategy GHN establish partnerships with global partners for the benefit of the Nordic Health Care market.
Pharmaelle Srl is an Italian pharmaceutical company which aim at developing Innovative Products, using Italian High Quality raw materials, Certified and Guaranteed, to offer physicians and their patients Excellent therapeutic alternatives. Pharmaelle invests constantly in R&D, working on different therapeutic areas such as Rare Diseases, Bariatric Surgery and Nutraceutics.
ALDIXYL
The Excellence in treatment of Adrenoleukodystrophy. Food for Special Medical Purposes (FSMP) developed for the treatment of ALD/AMN affected patients. Glyceryl Trioleate (GTO), Glyceryl Trierucate (GTE), Triglycerides of Conjugated Linoleic Acid (TGCLA), Alfaxyl (patented antioxidant mixture) and Vitamin E.
”With the possibility to introduce Aldixyl on the Nordic markets, our strategy to bring in high quality products and knowledge within rare metabolic diseases to the Nordic countries, is further strengthen. With a long track record within rare metabolic diseases we are convinced that the cooperation with Pharmaelle is an important step forward,” says Tina Madsen Sandström, chairman of GHN Pharma Metabolic.
Roberto Vico, CEO of Pharmaelle Srl, ”I am very pleased to start this collaboration with GHN Pharma. Our know-how will lead us to aim for Excellence for all our patients and customers. I am sure our cooperation will always be efficient and clear, in order to achieve the best results for both parties.”
